中华皮肤科杂志 ›› 2017, Vol. 50 ›› Issue (11): 855-859.doi: 10.3760/cma.j.issn.0412-4030.2017.11.022
程浩
收稿日期:2017-09-21
修回日期:2017-10-26
发布日期:2017-11-02
通讯作者:
程浩
E-mail:hz_chenghao@126.com
Cheng Hao
Received:2017-09-21
Revised:2017-10-26
Published:2017-11-02
摘要： 人乳头瘤病毒（human papillomavirus，HPV）是一种无包膜的小DNA病毒，可引起许多皮肤黏膜良性增生性疾病、宫颈癌、头颈癌和肛门直肠肿瘤等。全球27.9% ~ 30%的癌症与HPV感染有关［1］，预防HPV感染可减少HPV感染相关肿瘤发生。10余年来始陆续批准上市的预防性HPV疫苗有效地预防高危型HPV感染［2］，并间接保护未接种者。本文就预防性HPV疫苗临床应用中广受关注的问题，如预防感染作用、安全性、免疫接种指南推荐方案等作一综述……
程浩. 预防性人乳头瘤病毒疫苗的新进展[J]. 中华皮肤科杂志, 2017,50(11):855-859. doi:10.3760/cma.j.issn.0412-4030.2017.11.022
Cheng Hao. Prophylactic human papillomavirus vaccines[J]. Chinese Journal of Dermatology, 2017, 50(11): 855-859.doi:10.3760/cma.j.issn.0412-4030.2017.11.022
| ［1］ | zur Hausen H. Papillomaviruses in the causation of human cancers -a brief historical account［J］. Virology, 2009, 384（2）: 260⁃265. DOI: 10.1016/j.virol.2008.11.046. |
| ［2］ | Drolet M, Bénard É, Boily MC, et al. Population⁃level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta⁃analysis［J］. Lancet Infect Dis, 2015, 15（5）: 565⁃580. DOI: 10.1016/S1473⁃3099（14）71073⁃4. |
| ［3］ | Bernard HU, Burk RD, Chen Z, et al. Classification of papillo⁃maviruses （PVs） based on 189 PV types and proposal of taxonomic amendments［J］. Virology, 2010, 401（1）: 70⁃79. DOI: 10.1016/j.virol.2010.02.002. |
| ［4］ | Van Doorslaer K, Li Z, Xirasagar S, et al. The Papillomavirus Episteme: a major update to the papillomavirus sequence database［J］. Nucleic Acids Res, 2017, 45（D1）: D499⁃499D506. DOI: 10.1093/nar/gkw879. |
| ［5］ | de Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta⁃analysis［J］. Lancet Infect Dis, 2007, 7（7）: 453⁃459. DOI: 10.1016/S1473⁃3099（07）70158⁃5. |
| ［6］ | Winer RL, Feng Q, Hughes JP, et al. Risk of female human papillomavirus acquisition associated with first male sex partner［J］. J Infect Dis, 2008, 197（2）: 279⁃282. DOI: 10.1086/524875. |
| ［7］ | Bruni L, Diaz M, Castellsagué X, et al. Cervical human papillomavirus prevalence in 5 continents: meta⁃analysis of 1 million women with normal cytological findings［J］. J Infect Dis, 2010, 202（12）: 1789⁃1799. DOI: 10.1086/657321. |
| ［8］ | Cubie HA. Diseases associated with human papillomavirus infection［J］. Virology, 2013, 445（1⁃2）: 21⁃34. DOI: 10.1016/j.virol.2013.06.007. |
| ［9］ | World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014［J］. Wkly Epidemiol Rec, 2014, 89（43）: 465⁃491. |
| ［10］ | Bruni L, Barrionuevo⁃Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer （HPV Information Centre）. Human papillomavirus and related diseases in Botswana. Summary Report 27 July 2017. |
| ［11］ | Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008［J］. Sex Transm Dis, 2013, 40（3）: 187⁃193. DOI: 10.1097/OLQ.0b013e318286bb53. |
| ［12］ | de Sanjosé S, Alemany L, Ordi J, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva［J］. Eur J Cancer, 2013, 49（16）: 3450⁃3461. DOI: 10.1016/j.ejca.2013.06.033. |
| ［13］ | De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta⁃analysis［J］. Int J Cancer, 2009, 124（7）: 1626⁃1636. DOI: 10.1002/ijc.24116. |
| ［14］ | Harper DM, DeMars LR. HPV vaccines ⁃ A review of the first decade［J］. Gynecol Oncol, 2017, 146（1）: 196⁃204. DOI: 10.1016/j.ygyno.2017.04.004. |
| ［15］ | Naud PS, Roteli⁃Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV⁃16/18 AS04⁃adjuvanted vaccine: final analysis of a long⁃term follow⁃up study up to 9.4 years post⁃vaccination［J］. Hum Vaccin Immunother, 2014, 10（8）: 2147⁃2162. DOI: 10.4161/hv.29532. |
| ［16］ | World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017 ［J］. Wkly Epidemiol Rec, 2017, 92（19）: 241⁃268. |
| ［17］ | Nygård M, Saah A, Munk C, et al. Evaluation of the long⁃term anti⁃human papillomavirus 6 （HPV6）, 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine［J］. Clin Vaccine Immunol, 2015, 22（8）: 943⁃948. DOI: 10.1128/CVI.00133⁃15. |
| ［18］ | Garland SM, Kjaer SK, Muñoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: asystematic review of 10 years of real⁃world experience［J］. Clin Infect Dis, 2016, 63（4）: 519⁃527. DOI: 10.1093/cid/ciw354. |
| ［19］ | Quadrivalent vaccine against human papillomavirus to prevent high⁃grade cervical lesions［J］. N Engl J Med, 2007, 356（19）: 1915⁃1927. DOI: 10.1056/NEJMoa061741. |
| ［20］ | Joura EA, Giuliano AR, Iversen OE, et al. A 9⁃valent HPV vaccine against infection and intraepithelial neoplasia in women［J］. N Engl J Med, 2015, 372（8）: 711⁃723. DOI: 10.1056/NEJMoa1405044. |
| ［21］ | Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus （HPV）⁃16/18 AS04⁃adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types （PATRICIA）: final analysis of a double⁃blind, randomised study in young women［J］. Lancet, 2009, 374（9686）: 301⁃314. DOI: 10.1016/S0140⁃6736（09）61248⁃4. |
| ［22］ | Van Damme P, Olsson SE, Block S, et al. Immunogenicity and safety of a 9⁃valent HPV vaccine［J］. Pediatrics, 2015, 136（1）: e28⁃39. DOI: 10.1542/peds.2014⁃3745. |
| ［23］ | Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus （HPV）⁃6/11/16/18 vaccine on all HPV⁃associated genital diseases in young women［J］. J Natl Cancer Inst, 2010, 102（5）: 325⁃339. DOI: 10.1093/jnci/djp534. |
| ［24］ | Garland SM, Hernandez⁃Avila M, Wheeler CM, et al. Quadri⁃valent vaccine against human papillomavirus to prevent anogenital diseases［J］. N Engl J Med, 2007, 356（19）: 1928⁃1943. DOI: 10.1056/NEJMoa061760. |
| ［25］ | Wheeler CM, Skinner SR, Del RMR, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04⁃adjuvanted vaccine in women older than 25 years: 7⁃year follow⁃up of the phase 3, double⁃blind, randomised controlled VIVIANE study［J］. Lancet Infect Dis, 2016, 16（10）: 1154⁃1168. DOI: 10.1016/S1473⁃3099（16）30120⁃7. |
| ［26］ | Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04⁃adjuvanted vaccine in women older than 25 years: 4⁃year interim follow⁃up of the phase 3, double⁃blind, randomised controlled VIVIANE study［J］. Lancet, 2014, 384（9961）: 2213⁃2227. DOI: 10.1016/S0140⁃6736（14）60920⁃X. |
| ［27］ | Kreimer AR, González P, Katki HA, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial［J］. Lancet Oncol, 2011, 12（9）: 862⁃870. DOI: 10.1016/S1470⁃2045（11）70213⁃3. |
| ［28］ | Zhu FC, Hu SY, Hong Y, et al. Efficacy, immunogenicity, and safety of the HPV⁃16/18 AS04⁃adjuvanted vaccine in Chinese women aged 18⁃25 years: event⁃triggered analysis of a randomized controlled trial［J］. Cancer Med, 2017, 6（1）: 12⁃25. DOI: 10.1002/cam4.869. |
| ［29］ | Reisinger KS, Block SL, Lazcano⁃Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papilloma⁃virus types 6, 11, 16, 18 L1 virus⁃like particle vaccine in preadolescents and adolescents: a randomized controlled trial［J］. Pediatr Infect Dis J, 2007, 26（3）: 201⁃209. |
| ［30］ | Petäjä T, Keränen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus （HPV）⁃16/18 AS04⁃adjuvanted vaccine in healthy boys aged 10⁃18 years［J］. J Adolesc Health, 2009, 44（1）: 33⁃40. DOI: 10.1016/j.jadohealth.2008.10.002. |
| ［31］ | Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males［J］. N Engl J Med, 2011, 364（5）: 401⁃411. DOI: 10.1056/NEJMoa0909537. |
| ［32］ | Draper E, Bissett SL, Howell⁃Jones R, et al. Neutralization of non⁃vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera［J］. Vaccine, 2011, 29（47）: 8585⁃8590. DOI: 10.1016/j.vaccine.2011.09.021. |
| ［33］ | Kemp TJ, Hildesheim A, Safaeian M, et al. HPV16/18 L1 VLP vaccine induces cross⁃neutralizing antibodies that may mediate cross⁃protection［J］. Vaccine, 2011, 29（11）: 2011⁃2014. DOI: 10.1016/j.vaccine.2011.01.001. |
| ［34］ | Malagón T, Drolet M, Boily MC, et al. Cross⁃protective efficacy of two human papillomavirus vaccines: a systematic review and meta⁃analysis［J］. Lancet Infect Dis, 2012, 12（10）: 781⁃789. DOI: 10.1016/S1473⁃3099（12）70187⁃1. |
| ［35］ | Maver PJ, Poljak M. Progress in prophylactic human papilloma⁃virus （HPV） vaccination in 2016: A literature review［J］. Vaccine, 2017. DOI: 10.1016/j.vaccine.2017.07.113. |
| ［36］ | Draper E, Bissett SL, Howell⁃Jones R, et al. A randomized, observer⁃blinded immunogenicity trial of Cervarix® and Gardasil® Human Papillomavirus vaccines in 12⁃15 year old girls［J/OL］. PLoS One, 2013, 8（5）: e61825. DOI: 10.1371/journal.pone.0061825. |
| ［37］ | Cameron RL, Kavanagh K, Pan J, et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009⁃2013［J］. Emerg Infect Dis, 2016, 22（1）: 56⁃64. DOI: 10.3201/eid2201.150736. |
| ［38］ | Cuschieri K, Kavanagh K, Moore C, et al. Impact of partial bivalent HPV vaccination on vaccine⁃type infection: a population⁃based analysis［J］. Br J Cancer, 2016, 114（11）: 1261⁃1264. DOI: 10.1038/bjc.2016.97. |
| ［39］ | Godi A, Bissett SL, Miller E, et al. Relationship between humoral immune responses against HPV16, HPV18, HPV31 and HPV45 in 12⁃15 year old girls receiving cervarix® or gardasil® vaccine［J/OL］. PLoS One, 2015, 10（10）: e0140926. DOI: 10.1371/journal.pone.0140926. |
| ［40］ | Castellsagué X, Muñoz N, Pitisuttithum P, et al. End⁃of⁃study safety, immunogenicity, and efficacy of quadrivalent HPV （types 6, 11, 16, 18） recombinant vaccine in adult women 24⁃45 years of age［J］. Br J Cancer, 2011, 105（1）: 28⁃37. DOI: 10.1038/bjc.2011.185. |
| ［41］ | Schwarz T, Spaczynski M, Kaufmann A, et al. Persistence of immune responses to the HPV⁃16/18 AS04⁃adjuvanted vaccine in women aged 15⁃55 years and first⁃time modelling of antibody responses in mature women: results from an open⁃label 6⁃year follow⁃up study［J］. BJOG, 2015, 122（1）: 107⁃118. DOI: 10.1111/1471⁃0528.13070. |
| ［42］ | Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case⁃control study nested within a population based screening programme in Australia［J］. BMJ, 2014, 348: g1458. |
| ［43］ | Gertig DM, Brotherton JM, Budd AC, et al. Impact of a population⁃based HPV vaccination program on cervical abnormalities: a data linkage study［J］. BMC Med, 2013, 11: 227. DOI: 10.1186/1741⁃7015⁃11⁃227. |
| ［44］ | Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data［J］. Lancet Infect Dis, 2011, 11（1）: 39⁃44. DOI: 10.1016/S1473⁃3099（10）70225⁃5. |
| ［45］ | Baldur⁃Felskov B, Dehlendorff C, Munk C, et al. Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow⁃up of young Danish women［J］. J Natl Cancer Inst, 2014, 106（3）: djt460. DOI: 10.1093/jnci/djt460. |
| ［46］ | Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus （HPV） 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica［J/OL］. PLoS One, 2013, 8（7）: e68329. DOI: 10.1371/journal.pone.0068329. |
| ［47］ | Guo T, Eisele DW, Fakhry C. The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer［J］. Cancer, 2016, 122（15）: 2313⁃2323. DOI: 10.1002/cncr.29992. |
| ［48］ | Geier DA, Geier MR. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case⁃control assessment of the vaccine adverse event reporting system （VAERS） database［J］. Immunol Res, 2017, 65（1）: 46⁃54. DOI: 10.1007/s12026⁃016⁃8815⁃9. |
| ［49］ | Arnheim⁃Dahlström L, Pasternak B, Svanström H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study［J］. BMJ, 2013, 347: f5906. |
| ［50］ | Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine［J］. JAMA, 2009, 302（7）: 750⁃757. DOI: 10.1001/jama.2009.1201. |
| ［51］ | Human papillomavirus vaccines: WHO position paper, October 2014⁃Recommendations［J］. Vaccine, 2015, 33（36）: 4383⁃4384. DOI: 10.1016/j.vaccine.2014.12.002. |
| ［52］ | Kim DK, Riley LE, Harriman KH, et al. Recommended immunization schedule for adults aged 19 years or older, United States, 2017［J］. Ann Intern Med, 2017, 166（3）: 209⁃219. DOI: 10.7326/M16⁃2936. |
| ［53］ | Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices （ACIP）［J］. MMWR Recomm Rep, 2014, 63（RR⁃05）: 1⁃30. |
| ［54］ | Petrosky E, Bocchini JA, Hariri S, et al. Use of 9⁃valent human papillomavirus （HPV） vaccine: updated HPV vaccination recom⁃mendations of the advisory committee on immunization practices［J］. MMWR Morb Mortal Wkly Rep, 2015, 64（11）: 300⁃304. |
| ［55］ | Robinson CL, Romero JR, Kempe A, et al. Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger ⁃ United States, 2017［J］. MMWR Morb Mortal Wkly Rep, 2017, 66（5）: 134⁃135. DOI: 10.15585/mmwr.mm6605e1. |
| ［56］ | Meites E, Kempe A, Markowitz LE. Use of a 2⁃dose schedule for human papillomavirus vaccination ⁃ updated recommendations of the advisory committee on immunization practices［J］. MMWR Morb Mortal Wkly Rep, 2016, 65（49）: 1405⁃1408. DOI: 10.15585/mmwr.mm6549a5. |
| ［57］ | Saslow D, Castle PE, Cox JT, et al. American cancer society guideline for human papillomavirus （HPV） vaccine use to prevent cervical cancer and its precursors［J］. CA Cancer J Clin, 2007, 57（1）: 7⁃28. |
| ［58］ | Bosch FX, Robles C, Díaz M, et al. HPV⁃FASTER: broadening the scope for prevention of HPV⁃related cancer［J］. Nat Rev Clin Oncol, 2016, 13（2）: 119⁃132. DOI: 10.1038/nrclinonc.2015.146. |
| ［59］ | Kim KS, Park SA, Ko KN, et al. Current status of human papillomavirus vaccines［J］. Clin Exp Vaccine Res, 2014, 3（2）: 168⁃175. DOI: 10.7774/cevr.2014.3.2.168. |
| ［60］ | Gupta G, Glueck R, Rishi N. Physicochemical characterization and immunological properties of Pichia pastoris based HPV16L1 and 18L1 virus like particles［J］. Biologicals, 2017, 46: 11⁃22. DOI: 10.1016/j.biologicals.2016.12.002. |
| ［61］ | Schellenbacher C, Roden RB, Kirnbauer R. Developments in L2⁃based human papillomavirus （HPV） vaccines［J］. Virus Res, 2017, 231: 166⁃175. DOI: 10.1016/j.virusres.2016.11.020. |
| ［62］ | Schellenbacher C, Kwak K, Fink D, et al. Efficacy of RG1⁃VLP vaccination against infections with genital and cutaneous human papillomaviruses［J］. J Invest Dermatol, 2013, 133（12）: 2706⁃2713. DOI: 10.1038/jid.2013.253. |
| No related articles found! |
|
